Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aligos Therapeutics, Inc.ALGS · Entity 7352 | See Remarks | March 09, 2026 | March 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aligos Therapeutics, Inc.
Report date March 09, 2026 · Filed March 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.03 · Expires 2036-03-09 | Direct | 23,310 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 23,310 · Balance 23,310 F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 11, 2026 20:19 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 23,310 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001610717-26-000095 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,310 Underlying: Common Stock · 23,310 shares Expires 2036-03-09 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 21:14 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $8.68 | $0.00 |
DisclosureSEC source: 0001610717-25-000289 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2035-07-16 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 16, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:33 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 21,693 | $0.00 Strike: $16.87 | $0.00 |
DisclosureSEC source: 0001610717-25-000045 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,693 Underlying: Common Stock · 21,693 shares Expires 2035-02-28 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 28, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:22 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 10,880 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001610717-24-000464 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,880 Underlying: Common Stock · 10,880 shares Expires 2034-09-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from September 4, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:42 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001610717-24-000122 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 1, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 6 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 74,998 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 5 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,998 Underlying: Common Stock · 74,998 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. F5 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 58,822 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 4 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,822 Underlying: Common Stock · 58,822 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 3 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 2 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:06 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000274 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:11 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005256 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:12 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013865 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:09 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002893 · doc1.xml · derivative · entry 2 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F2 · derivative.exercise_date: 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:09 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001567619-22-002893 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 01:05 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001567619-20-020625 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from December 1, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-2 Preferred Stock · Derivative | 1,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · derivative · entry 6 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,452 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries B-1 Preferred Stock · Derivative | 3,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · derivative · entry 5 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionSeries A Preferred Stock · Derivative | 13,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · derivative · entry 4 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,671 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 1,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · nonDerivative · entry 3 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 3,394 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · nonDerivative · entry 2 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
| October 20, 2020 Filed Oct 20, 2020 20:57 UTC | Aligos Therapeutics, Inc. ALGS · Entity 7352 | ConversionCommon Stock | 13,671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-018006 · doc1.xml · nonDerivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the issuer's Series A Preferred Stock, Series B-1 Preferred Stock and Series B-2 Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on October 20, 2020 and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.